----item----
version: 1
id: {32541B0F-7A80-4C1B-B129-18B7FD8595F5}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/20/bluebird to seek early approvals for blood disorder drug
parent: {9272B77E-1398-4EF1-A77A-17C397C8C6D1}
name: bluebird to seek early approvals for blood disorder drug
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 979fb7cf-caf6-4191-8bee-39bb782fabf4

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 56

bluebird to seek early approvals for blood disorder drug
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 56

bluebird to seek early approvals for blood disorder drug
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1914

<p>Shares of bluebird bio got a 9% boost on 19 May after the company revealed its plans to seek early approvals in the US and Europe to market its gene therapy LentiGlobin BB305 as a treatment beta-thalassemia major, a serious blood disorder. </p><p>The company said it plans to pursue an accelerated approval from the FDA and a conditional approval from the European Medicines Agency (EMA) based on recent discussions it had with regulators from both agencies, which agreed with the company on seeking the pathways.</p><p>On 2 February, Bluebird revealed it had gained the FDA's breakthrough designation for LentiGlobin as a treatment for transfusion-dependent patients with beta-thalassemia major.</p><p>Bluebird noted it is one of the first companies to participate in the EMA's Adaptive Pathways pilot program, which is part of the agency's efforts to improve timely access for patients to new medicines. </p><p>The firm plans to base its European application on its beta-thalassemia major clinical study, known as Northstar study, with supportive data from its HGB-205 trial. </p><p>Conversion to full approval will be subject to the successful completion of the HGB-207 and HGB-208 clinical trials, supportive long-term follow-up data and real-life post-approval monitoring data. </p><p>The firm said it reach an agreement with the FDA on the design of the firm's planned HGB-207 and HGB-208 trials. </p><p>Based on its discussions with the FDA, bluebird bio said the data from those trials, plus its ongoing beta-thalassemia major clinical studies &ndash; Northstar and HGB-205 &ndash; could form the basis for a biolotics license application submission for LentiGlobin BB305. </p><p>The company said its HGB-207 and HGB-208 trials share similar designs, but are differentiated primarily by patient age. </p><p>Shares of the firm closed at $170.53 on 19 May, up $14.13, or 9%.</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 247

<p>Shares of bluebird bio got a 9% boost on 19 May after the company revealed its plans to seek early approvals in the US and Europe to market its gene therapy LentiGlobin BB305 as a treatment beta-thalassemia major, a serious blood disorder. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 56

bluebird to seek early approvals for blood disorder drug
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150520T050004
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150520T050004
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150520T050004
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028766
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 56

bluebird to seek early approvals for blood disorder drug
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358412
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042347Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

979fb7cf-caf6-4191-8bee-39bb782fabf4
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042347Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
